Crossmark

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Crossref DOI link: https://doi.org/10.14283/jpad.2022.63

Published Print: 2022-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Wischik, Claude M.

Bentham, P.

Gauthier, S.

Miller, S.

Kook, K.

Schelter, B.O.
License Information

Text and Data Mining valid from 2022-10-01

Text and Data Mining valid from 2022-10-01

Version of Record valid from 2022-06-26
More Information

This article is maintained by: Elsevier

Article Title: Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2022.63

Content Type: article

Copyright: Copyright © 2022 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below